Meptid (Meptazinol)

Meptazinol works by partially activating mu‑opioid receptors, which produces analgesia while limiting the maximal respiratory depression. At the same time it blocks kappa‑opioid receptors, contributing to its pain‑relieving effect and reducing dysphoric responses that can be seen with some opioids.

The exact dose of Meptid is individualized by the prescribing clinician based on the patient’s pain intensity, previous opioid exposure, age, and organ function. The prescriber determines the appropriate starting dose and any subsequent titration, following local prescribing guidelines.

Safety data for Meptazinol during pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and only under close medical supervision.

To request Meptid, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with full‑agonist opioids such as morphine, Meptid offers a ceiling effect on respiratory depression, potentially lowering the risk of severe respiratory compromise. However, its analgesic potency is moderate, and it may be less suitable for very severe pain where stronger opioids are required.

Meptid should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and do not use it after the expiry date printed on the label.

Meptid is administered orally. The tablet should be swallowed whole with a glass of water and not chewed, crushed, or dissolved, unless otherwise directed by a healthcare professional.

The most serious risks include respiratory depression, severe hypotension, and allergic reactions such as anaphylaxis. Patients should be monitored closely during initiation, especially if they have underlying respiratory conditions or are taking other depressant medications.

Meptid is contraindicated in individuals with known hypersensitivity to Meptazinol or other phenylpiperidine opioids, in patients with severe respiratory depression, and in those for whom opioid therapy is inappropriate due to a history of opioid misuse or addiction.